Jazz Pharmaceuticals Inc. (JAZZ) reported fourth-quarter net income of $37.5 million or $0.79 per share, compared to $24.5 million or $0.56 per share in the prior year quarter.
On an adjusted basis, net income for the fourth quarter rose to $55.4 million or $1.17 per share from $27.2 million or $0.63 per share in the comparable quarter last year. On average, six analysts polled by Thomson Reuters expected earnings of $1.09 per share for the quarter. Analysts' estimates typically exclude one-time items.
Total revenues for the quarter were $83.54 million, compared with $53.37 million in the previous year quarter, while five analysts estimated revenues of $80.84 million for the quarter.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.